Home › Research › Biomarkers
Biomarker Modeling of Alzheimer’s Disease
Clifford R. Jack, David M. Holtzman. Neuron, 2013-12-01
Topic: Amyloid, tau and blood-test diagnosis
This review discusses time-dependent models of Alzheimer's disease (AD) that track the temporal evolution of validated pathophysiological biomarkers relative to age of onset, aging, and co-occurring brain pathologies. It notes that five validated biomarkers—three imaging measures and two cerebrospinal fluid analytes—measure amyloid-β plaques and tau-related neurodegeneration. These biomarkers do not evolve identically, but rather in a sequential and temporally overlapping manner prior to overt clinical symptoms.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jack, C. R., & Holtzman, D. M. (2013). Biomarker Modeling of Alzheimer’s Disease. Neuron. https://doi.org/10.1016/j.neuron.2013.12.003
Vancouver
Jack CR, Holtzman DM. Biomarker Modeling of Alzheimer’s Disease. Neuron. 2013. doi:10.1016/j.neuron.2013.12.003. PMID: 24360540.
BibTeX
@article{jack2013-24360540,
author = {Jack, Clifford R. and Holtzman, David M.},
title = {{Biomarker Modeling of Alzheimer’s Disease}},
journal = {Neuron},
year = {2013},
doi = {10.1016/j.neuron.2013.12.003},
pmid = {24360540},
url = {https://doi.org/10.1016/j.neuron.2013.12.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials.
- Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration.
- Three of the five are imaging measures and two are cerebrospinal fluid analytes.
- AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner.
Why it matters
Discusses modeling of biomarkers in Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
How this study scored 58/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 55 of the 95 points we could judge it on, which is 58 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuron) |
| Journal's citation record | 4 / 4 | Neuron: journal h-index 689 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,015 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 67.7 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 6 / 6 | Cited 42.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 207 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David M. Holtzman: h-index 206 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24360540) |
| Free to read | 2 / 2 | Free to read |
| Points | 55 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 95 points we could judge it on is 58 out of 100. |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also in Biomarkers
150 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.